

Nicole Concin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7082873/publications.pdf>

Version: 2024-02-01

65
papers

3,183
citations

257450

24
h-index

161849

54
g-index

66
all docs

66
docs citations

66
times ranked

3829
citing authors

#	ARTICLE	IF	CITATIONS
1	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer, 2021, 31, 12-39.	2.5	859
2	ESMOâ€“ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Annals of Oncology, 2019, 30, 672-705.	1.2	665
3	Clinical Relevance of E2F Family Members in Ovarian Cancerâ€“An Evaluation in a Training Set of 77 Patients. Clinical Cancer Research, 2007, 13, 144-151.	7.0	103
4	ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 153-190.	2.8	99
5	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Radiotherapy and Oncology, 2021, 154, 327-353.	0.6	96
6	Clinical Relevance of Dominant-Negative p73 Isoforms for Responsiveness to Chemotherapy and Survival in Ovarian Cancer: Evidence for a Crucial p53-p73 Cross-talk In vivo. Clinical Cancer Research, 2005, 11, 8372-8383.	7.0	89
7	Mineral oil in human tissues, Part I: Concentrations and molecular mass distributions. Food and Chemical Toxicology, 2014, 72, 312-321.	3.6	77
8	BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients â€“ A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). European Journal of Cancer, 2014, 50, 2090-2098.	2.8	75
9	Mineral oil paraffins in human body fat and milk. Food and Chemical Toxicology, 2008, 46, 544-552.	3.6	72
10	Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer. BMC Cancer, 2016, 16, 102.	2.6	68
11	Recommended Guidelines for Validation, Quality Control, and Reporting of <i>TP53</i> Variants in Clinical Practice. Cancer Research, 2017, 77, 1250-1260.	0.9	68
12	Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. International Journal of Gynecological Cancer, 2020, 30, 436-440.	2.5	61
13	Uterine serous carcinoma. Gynecologic Oncology, 2021, 162, 226-234.	1.4	58
14	ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors. International Journal of Gynecological Cancer, 2021, 31, 961-982.	2.5	54
15	Mineral oil in human tissues, Part II: Characterization of the accumulated hydrocarbons by comprehensive two-dimensional gas chromatography. Science of the Total Environment, 2015, 506-507, 644-655.	8.0	50
16	ESGOâ€“SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers. Lancet Oncology, The, 2020, 21, e360-e368.	10.7	50
17	The genetic landscape of 87 ovarian germ cell tumors. Gynecologic Oncology, 2018, 151, 61-68.	1.4	44
18	Use of Underarm Cosmetic Products in Relation to Risk of Breast Cancer: A Case-Control Study. EBioMedicine, 2017, 21, 79-85.	6.1	43

#	ARTICLE	IF	CITATIONS
19	<scp>ESGO</scp>/<scp>ISUOG</scp>/<scp>IOTA</scp>/<scp>ESGE</scp> Consensus Statement on preoperative diagnosis of ovarian tumors. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 58, 148-168.	1.7	42
20	Prognostic Relevance of Pretherapeutic Gamma-Glutamyltransferase in Patients with Primary Metastatic Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0125317.	2.5	40
21	Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer. <i>Oncogene</i> , 2011, 30, 4038-4049.	5.9	39
22	E2F3a Is Critically Involved in Epidermal Growth Factor Receptorâ€“Directed Proliferation in Ovarian Cancer. <i>Cancer Research</i> , 2010, 70, 4613-4623.	0.9	32
23	Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies. <i>Gynecologic Oncology</i> , 2020, 156, 308-314.	1.4	32
24	Suppression of acetylpolyamine oxidase by selected AP-1 members regulates DNp73 abundance: mechanistic insights for overcoming DNp73-mediated resistance to chemotherapeutic drugs. <i>Cell Death and Differentiation</i> , 2014, 21, 1240-1249.	11.2	29
25	Evidence for Cosmetics as a Source of Mineral Oil Contamination in Women. <i>Journal of Women's Health</i> , 2011, 20, 1713-1719.	3.3	27
26	Combining conventional therapy with immunotherapy: Aâ€“risky business?. <i>European Journal of Cancer</i> , 2019, 113, 41-44.	2.8	25
27	The role of HE4 for prediction of recurrence in epithelial ovarian cancer patientsâ€“results from the OVCAD study. <i>Tumor Biology</i> , 2016, 37, 3009-3016.	1.8	23
28	Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancerâ€“A Study of the GANNET53 Consortium. <i>Frontiers in Oncology</i> , 2019, 9, 832.	2.8	23
29	Clear cell carcinoma of the endometrium. <i>Gynecologic Oncology</i> , 2022, 164, 658-666.	1.4	23
30	HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium. <i>OncoTargets and Therapy</i> , 2014, 7, 1563.	2.0	18
31	Polymer-Ligand-Based ELISA for Robust, High-Throughput, Quantitative Detection of p53 Aggregates. <i>Analytical Chemistry</i> , 2018, 90, 13273-13279.	6.5	18
32	Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells. <i>Cell Death and Differentiation</i> , 2017, 24, 300-316.	11.2	16
33	Jump in the fire â€“ heat shock proteins and their impact on ovarian cancer therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 152-156.	4.4	15
34	Fetal weight estimation at term â€“ ultrasound versus clinical examination with Leopoldâ€™s manoeuvres: a prospective blinded observational study. <i>BMC Pregnancy and Childbirth</i> , 2019, 19, 122.	2.4	15
35	European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1508-1529.	2.5	13
36	The relative risk of second primary cancers in Austriaâ€™s western states: a retrospective cohort study. <i>BMC Cancer</i> , 2017, 17, 699.	2.6	12

#	ARTICLE	IF	CITATIONS
37	Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival. <i>Histopathology</i> , 2018, 73, 1002-1012.	2.9	12
38	̢-Glutamyltransferase and Breast Cancer Risk Beyond Alcohol Consumption and Other Life Style Factors – A Pooled Cohort Analysis. <i>PLoS ONE</i> , 2016, 11, e0149122.	2.5	11
39	Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients – A study of the OVCAD consortium. <i>Gynecologic Oncology</i> , 2018, 149, 371-380.	1.4	11
40	The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer – A Study of the OVCAD Consortium. <i>Cancers</i> , 2021, 13, 2613.	3.7	10
41	L1CAM in the Early Enteric and Urogenital System. <i>Journal of Histochemistry and Cytochemistry</i> , 2017, 65, 21-32.	2.5	9
42	Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 713-720.	2.5	7
43	The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer – A Retrospective Study. <i>PLoS ONE</i> , 2017, 12, e0169272.	2.5	7
44	Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB–IIB cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 824-828.	2.5	6
45	Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 5567-5567.	1.6	5
46	ABO blood groups and rhesus factor expression as prognostic parameters in patients with epithelial ovarian cancer – a retrospective multi-centre study. <i>BMC Cancer</i> , 2018, 18, 447.	2.6	4
47	Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium. <i>Anticancer Research</i> , 2016, 36, 1015-22.	1.1	4
48	Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study. <i>Cancers</i> , 2022, 14, 1780.	3.7	4
49	European Network of Gynaecological Oncological Trial Groups – requirements for trials between academic groups and industry partners – a new Model D for drug and medical device development. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 730-734.	2.5	3
50	Definition and Independent Validation of a Proteomic-Classifer in Ovarian Cancer. <i>Cancers</i> , 2020, 12, 2519.	3.7	3
51	BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer. <i>Genes</i> , 2021, 12, 969.	2.4	3
52	Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer – A Study of the OVCAD Consortium. <i>Cancers</i> , 2021, 13, 5865.	3.7	3
53	Response to: Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with) Tj ETQq1 1 0.784314 rgBT /Ove Gynecological Cancer, 2021, 31, ijgc-2021-002668.	2.5	2
54	Efficacy and safety of lucitanib + nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO). <i>Journal of Clinical Oncology</i> , 2022, 40, 5517-5517.	1.6	2

#	ARTICLE	IF	CITATIONS
55	Primary chemotherapy and maintenance therapy in epithelial ovarian cancer. Memo - Magazine of European Medical Oncology, 2008, 1, 99-102.	0.5	1
56	Response to: Correspondence on "ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors" by Thomassin-Nagarra et al. International Journal of Gynecological Cancer, 2021, 31, 1396-1397.	2.5	1
57	Phase I results of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.. Journal of Clinical Oncology, 2016, 34, e17038-e17038.	1.6	1
58	Interval versus primary tumor debulking surgery in advanced ovarian cancer: Analysis of the European OVCAD data.. Journal of Clinical Oncology, 2012, 30, 5071-5071.	1.6	1
59	Implementing clinical practice guidelines: time to assess it. ESMO Open, 2020, 5, e001130.	4.5	0
60	Nomogram prediction for overall survival of patients diagnosed with cervical cancer.. Journal of Clinical Oncology, 2012, 30, 5111-5111.	1.6	0
61	The role of gamma-glutamyltransferase in malignant transformation and prognosis of ovarian cancer.. Journal of Clinical Oncology, 2013, 31, e16524-e16524.	1.6	0
62	Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.. Journal of Clinical Oncology, 2015, 33, 5578-5578.	1.6	0
63	Clinical characterization of long term survivors (LTS) in ovarian cancer (OC): Results of a propensity score matched (PSM) analysis of the international prospective tumor bank for ovarian cancer (TOC) Tj ETQq1 1 0.784314 rgBT /Overl	1.6	0
64	EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the HSP90 inhibitor ganetespib with carboplatin followed by maintenance treatment with niraparib (+/-) Tj ETQq0 0 0 9.6 /Overlck 10 Tf 5 platinum-sensitive ovarian cancer patients.. Journal of Clinical Oncology, 2019, 37, TPS5605-TPS5605.	1.6	0
65	Interviews from the European Society of Gynaecological Oncology 2021 Congress: an IJGC-ENYGO Fellows compilation. International Journal of Gynecological Cancer, 2022, 32, 468-473.	2.5	0